CLINICAL TRIAL: NSABP P-2: STAR

临床试验：NSABP P-2：STAR

• 批准号: 7719086
• 负责人: Scott Henry Kurtzman
• 金额: $ 1.19万
• 依托单位: UNIVERSITY OF CONNECTICUT SCH OF MED/DNT
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-04-01 至 2009-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7719086
• 关键词: Clinical Trials; Computer Retrieval of Information on Scientific Projects Database; Development; Endometrial Carcinoma; Evaluation; Funding; Goals; Grant; In Situ; Incidence; Institution; Invasive; National Surgical Adjuvant Breast and Bowel Project; Osteoporosis prevention; Outcome; P-2; Patients; Pharmaceutical Preparations; Postmenopause; Raloxifene; Rate; Research; Research Personnel; Resources; Source; Tamoxifen; United States National Institutes of Health; Woman; disorder risk; malignant breast neoplasm; prevent

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. In the P-1 study, tamoxifen was shown to prevent the development of invasive and in situ breast cancer. Raloxifene has shown to be an effective drug for the prevention of osteoporosis. It was observed in the Multiple Outcomes of Raloxifene Evaluation (MORE) trial that there were fewer breast cancers in the group of patients that had taken raloxifene compared to the controls. This study will determine if raloxifene is either more or less effective than tamoxifen in reducing the incidence of invasive breast cancer in postmenopausal women who are at increased risk for the disease. A secondary goal is to determine whether raloxifene reduces the endometrial cancer rate compared to tamoxifen.

这个子项目是众多研究子项目之一